Second-line virologic failure and elevated bilirubin as a potential surrogate marker of ART adherence among people living with HIV in Eastern Uganda
Simiyu Melap Lynnet, Jacob Stanley Iramiot, Rebecca Nekaka, Patrick Okware, Mary Abwola Olwedo, Joshua Epuitai, Paul Oboth, Herbert Itabangi, Lydia V. N. Ssenyonga, Julius Nteziyaremye, David Okia

TL;DR
The study found that elevated bilirubin is not a reliable indicator of ART adherence or virologic failure in HIV patients in Uganda.
Contribution
This study evaluates bilirubin as a potential surrogate marker for ART adherence and virologic failure in a specific regional context.
Findings
The prevalence of virological failure among participants was 7.5%.
Elevated bilirubin levels showed poor sensitivity and specificity for predicting adherence or virological failure.
Routine viral load monitoring is emphasized over using bilirubin as a marker.
Abstract
Second-line antiretroviral therapy (ART) failure remains a challenge in HIV Programs. We conducted a cross-sectional study among people living with HIV on second-line ART in Eastern Uganda to determine the prevalence and associated factors of virological failure and to assess elevated serum bilirubin as a surrogate marker of adherence. The prevalence of virological failure was 7.5%. Elevated bilirubin showed poor sensitivity and specificity for predicting adherence or virological failure. The findings highlight the need for routine viral load monitoring, as bilirubin is not a reliable surrogate marker of treatment adherence or virological failure.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · HIV-related health complications and treatments
